Financial Performance - The company's revenue for the year ended December 31, 2022, was approximately HKD 610.3 million, a decrease of 3.6% compared to HKD 632.9 million in 2021[41]. - The adjusted gross profit margin for 2022 was 45.2%, down from 50.1% in 2021[42]. - The net profit attributable to the company's owners for 2022 was HKD 89.5 million, compared to HKD 133.6 million in 2021, reflecting a decline of approximately 33%[17]. - The group's gross profit for the year ended December 31, 2022, was approximately HKD 270.8 million, a decrease of 13.3% compared to 2021[55]. - The total revenue for the year ended December 31, 2022, was HKD 610,291,000, a decrease of 3.6% compared to HKD 632,931,000 in 2021[121]. - The gross profit for the same period was HKD 270,844,000, reflecting a decline of 13.3% from HKD 312,545,000 in the previous year[121]. - Adjusted net profit after tax was HKD 101,232,000, down 26.3% from HKD 137,278,000 in 2021[121]. - The operating profit for the year ended December 31, 2022, was HKD 132,807 thousand, down from HKD 191,262 thousand in 2021, a decline of around 30.5%[145]. - The total comprehensive income for the year ended December 31, 2022, was HKD 3,286 thousand, significantly lower than HKD 64,726 thousand in 2021, a decrease of about 95.9%[145]. - The company reported a net loss of HKD 701,000 in 2022, compared to a net gain of HKD 1,572,000 in 2021[173]. Revenue Breakdown - Revenue from Germany for the year was approximately HKD 335.6 million, a decrease of about 16.9% compared to 2021, accounting for approximately 55.0% of total revenue[30]. - Revenue from the group's operations in China for the year ended December 31, 2022, was approximately HKD 98.4 million, a decrease of about 33.9% compared to 2021, accounting for approximately 16.1% of total revenue[56]. - Revenue from the group's operations in Denmark for the year ended December 31, 2022, was approximately HKD 65.1 million, a decrease of about 18.5% compared to 2021, accounting for approximately 10.7% of total revenue[57]. - Revenue from ICL implantation procedures was approximately HKD 71.8 million, a decrease of about 19.7% compared to 2021, accounting for approximately 12.0% of total surgical revenue[59]. - The revenue from the German segment for the year ended December 31, 2022, was HKD 407,249 thousand, while the Chinese segment generated HKD 149,012 thousand[156]. Operational Challenges - The company faced operational disruptions in China due to COVID-19, impacting outpatient consultations and surgery bookings[27]. - The company experienced a decline in revenue from crystal replacement surgeries in Germany, China, and Denmark, with decreases of approximately 9.3%, 37.8%, and 18.2% respectively[32]. - The company completed its first surgery at a new clinic in Copenhagen in March 2022 after a delay of approximately 60 days due to COVID-19 restrictions[28]. - The company recorded a significant increase in employee benefit expenses, which rose by 29.1% to HKD 140.9 million in 2022[39]. Future Plans and Expansion - The group plans to open its first clinic in Hong Kong in the second half of 2023, located in Causeway Bay[73]. - The group is constructing three new clinics in Germany, expected to commence operations in the second half of 2023[74]. - The group plans to establish satellite clinics in Beijing and Shanghai, which will enhance the utilization of existing surgical centers and penetrate high-potential cities[84]. - The second clinic in London is nearly completed and is set to begin trial operations in Q2 2023[104]. - The group is actively pursuing acquisition opportunities, particularly targeting renowned private ophthalmology clinics in Europe[75]. Financial Position - As of December 31, 2022, the current ratio was approximately 5.1, down from 6.7 in 2021[88]. - The group had no long-term borrowings as of December 31, 2022, compared to an asset-liability ratio of approximately 0.26% in 2021[89]. - The total assets of the company increased to HKD 1,541,040,000 as of December 31, 2022, compared to HKD 1,369,022,000 in 2021[130]. - Total liabilities rose to HKD 497,947,000, compared to HKD 328,545,000 in the previous year[131]. - The company reported a financial expense of HKD 10,737 thousand for the year ended December 31, 2022, compared to HKD 8,465 thousand in 2021, an increase of approximately 26.8%[145]. Shareholder Information - The company announced a dividend of HKD 0.09932 per share for the year ended December 31, 2021, totaling HKD 33.1 million, which was approved and paid in 2022[26]. - The company proposed a final dividend of HKD 0.06266 per share, totaling approximately HKD 20,880,818, subject to shareholder approval[114]. - The number of shares outstanding at the end of 2022 was 210,598,000, down from 480,411,000 in 2021, indicating a reduction of 56.1%[175].
德视佳(01846) - 2022 - 年度业绩